Tamtam Try Tamtam free
Fresenius Group logo

Fresenius Group account plan

Healthcare products and services

At a glance

Fresenius is a German healthcare group: Fresenius Kabi (IV drugs, nutrition, MedTech, biosimilars) and Helios hospitals. €22,554 million 2025 revenue.

Fresenius SE & Co. KGaA, headquartered in Bad Homburg, Germany, is a therapy-focused healthcare group with two Operating Companies: Fresenius Kabi (generic IV drugs and fluids, clinical nutrition, MedTech and biosimilars) and Fresenius Helios (private hospitals in Germany and in Spain through Quirónsalud). It also holds a ~29% equity-accounted stake in Fresenius Medical Care. In 2025 revenue was €22,554 million (7% organic growth), EBIT before special items €2,595 million (11.5% margin) and Core EPS €2.87, with 178,394 employees; Europe is 74% of revenue and North America 12%. The Else Kröner-Fresenius-Stiftung held 27.1% of the shares at December 31, 2025.

Business units

Strategic priorities

#FutureFresenius Rejuvenate phase
After Reset and Revitalize, the group is upgrading its core and scaling three platforms, (Bio)Pharma, MedTech and Care Provision, mainly organically with partnering, in-licensing and potentially bolt-on acquisitions.
Scale Kabi's growth vectors
Kabi's structural EBIT margin band rises to 17-19% from 2026; products launched since 2023 generated more than €500 million of 2025 revenue, and Biopharma aims to double revenue by 2030.
Close the Helios performance gap
Management calls Helios a clear priority for 2026: cluster strategy, administrative consolidation and case-mix management in Germany, within a 10-12% margin ambition.
Core EPS growth
From 2026 Core EPS replaces EBIT as the guided metric; FY2026 Core EPS growth guidance was raised in August to 10-15% in constant currency.
Digital healthcare and AI
A strategic partnership with SAP to build a digital healthcare ecosystem, AI tools at Quirónsalud and IT harmonisation and administrative digitalisation in Germany.

Latest results

In Q2 2026 revenue was €5,864 million (6% organic) and EBIT before special items €719 million at a 12.3% margin, with Core EPS of €0.83 (+14%). Over H1 2026 revenue was €11,608 million (5% organic), EBIT €1,397 million and net income before special items €1,118 million (+14%). Kabi's growth vectors reached a 17.9% Q2 margin and Biopharma grew 37%, while Helios lifted its Q2 margin to 10.6%. Net debt fell to €10,138 million (2.6x). FY2026 guidance is 4-7% organic revenue growth and Core EPS growth of 10-15% in constant currency, raised from 5-10%.

Investments and deals

Capex step-up
Capex is guided at about 5.5% of revenue in 2026 (54% at Helios, 39% at Kabi), up from 4.4% in 2025, when property, plant and equipment spending was €1,001 million.
Kabi capacity
Projects include high-speed infusion-bottle lines in Italy and Poland, a €36 million sip-feed line in the Netherlands, a multi-chamber bag line in China, €50 million in MedTech capacity and automation, and the Wilson, North Carolina plant ramp-up.
Biosimilar pipeline
Acquisition spending of €392 million in 2025 went mainly to milestone payments for the biosimilars business acquired from Merck KGaA; vedolizumab filings were accepted in the U.S. and EU and rituximab won FDA approval.
Portfolio exits
The Vamed exit is largely completed, about €1.1 billion was raised from FMC shares and an exchangeable bond in March 2025, and three German hospitals are being sold.

Challenges and risks

German hospital financing
The GKV contribution-rate stabilisation act limits DRG base-rate increases from January 1, 2027, and the hospital structure reform makes 60% of remuneration volume-independent.
U.S. tariffs and FDA oversight
U.S. tariffs, the weaker dollar and other factors created several hundred million euros of headwinds in 2025; the Melrose Park, Illinois site received an FDA Official Action Indicated classification.
China volume-based procurement
The Ketosteril tender in China weighed on Nutrition, and management says volume-based tendering is there to stay.
U.S. generics pricing and buyer concentration
Pharma faces U.S. pricing pressure, and Kabi's U.S. sales depend on a limited number of buyers.
Middle East conflict and supply chain
The conflict raised energy, transport and material cost risks in 2026.

What leadership says

“Helios is not yet delivering in line with our expectations. Closing this gap is a clear management priority for 2026 and beyond.”

Michael Sen, Chief Executive Officer · Q4 and full-year 2025 results call, 25 February 2026

“Q2 is another clear proof point that #FutureFresenius is delivering. We are converting operational momentum into earnings growth, higher returns, and stronger financial and strategic flexibility.”

Michael Sen, Chief Executive Officer · Q2 2026 results call, 5 August 2026

“R&D is not the leakage. R&D is securing your future.”

Michael Sen, Chief Executive Officer · Q4 and full-year 2025 results call, 25 February 2026

“We have more opportunities than we probably have funding for”

Sara Hennicken, Chief Financial Officer · Q4 and full-year 2025 results call, 25 February 2026

Where a supplier can help

Hospital efficiency and automation at Helios
Closing the Helios gap and answering the GKV stabilisation act with efficiency, automation and digitalisation programmes creates demand for administrative automation, case-mix analytics and IT harmonisation services.
Manufacturing quality and automation at Kabi
The FDA classification at Melrose Park, which management sees as a chance to embed automation and digitisation, plus new production lines, favour GMP, quality and automation suppliers.
Clinical AI and digital platforms
Quirónsalud's AI tools and the SAP digital healthcare ecosystem open room for clinical documentation, AI and data platform partners.
Supply chain resilience
U.S. tariffs, the Middle East conflict and the Local-for-Local push create needs for alternative API sourcing, U.S. manufacturing and logistics partners.
Biosimilar commercialisation
Doubling Biopharma by 2030 with new launches and direct health-plan contracting fits market access, distribution and CDMO capacity offers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Fresenius Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Fresenius Group

What does Fresenius do?

Fresenius runs Fresenius Kabi, which makes generic IV drugs and fluids, clinical nutrition, infusion devices and biosimilars, and Fresenius Helios, which operates private hospitals in Germany and Spain.

What was Fresenius' revenue in 2025?

Revenue was €22,554 million in 2025 with 7% organic growth, EBIT before special items of €2,595 million and Core EPS of €2.87.

How many employees does Fresenius have?

178,394 employees at the end of 2025, and 178,486 at June 30, 2026; Helios accounts for 130,240 of the 2025 total.

Who leads Fresenius?

Michael Sen is CEO, with his mandate extended to 2031; Sara Hennicken is CFO, Pierluigi Antonelli oversees Fresenius Kabi and Dr. Christian Pawlu oversees Helios from July 1, 2026.

What is Fresenius' strategy?

Under #FutureFresenius it is scaling three platforms, (Bio)Pharma, MedTech and Care Provision, growing biosimilars and MedTech while lifting Helios margins and Core EPS.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)